## Jan Bonhoeffer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11428819/publications.pdf

Version: 2024-02-01

		236612	253896
58	1,977	25	43
papers	citations	h-index	g-index
F.O.	<b></b>	<b></b>	2221
58	58	58	2321
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Three-Year Surveillance of Intussusception in Children in Switzerland. Pediatrics, 2007, 120, 473-480.	1.0	135
2	The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine, 2002, 21, 298-302.	1.7	134
3	Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ: British Medical Journal, 2011, 343, d3908-d3908.	2.4	127
4	International collaboration to assess the risk of Guillain Barr $\tilde{A}$ © Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 2013, 31, 4448-4458.	1.7	91
5	Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower Respiratory Tract Infection in Children and Adolescents (ProPAED): A Randomized Controlled Trial. PLoS ONE, 2013, 8, e68419.	1.1	90
6	Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 557-562.	1.7	89
7	Vasculitis as an adverse event following immunization – Systematic literature review. Vaccine, 2016, 34, 6641-6651.	1.7	87
8	The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine, 2007, 25, 5671-5674.	1.7	80
9	Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. European Journal of Pediatrics, 2005, 164, 366-370.	1.3	76
10	Global alignment of immunization safety assessment in pregnancy – The GAIA project. Vaccine, 2016, 34, 5993-5997.	1.7	72
11	Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. PLoS ONE, 2014, 9, e82222.	1.1	53
12	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. Vaccine, 2018, 36, 6202-6211.	1.7	53
13	The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiology and Drug Safety, 2003, 12, 335-340.	0.9	50
14	Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine, 2009, 27, 2282-2288.	1.7	48
15	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006.	1.7	42
16	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	1.7	41
17	A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine, 2012, 30, 3042-3046.	1.7	39
18	Standardized case definitions of adverse events following immunization (AEFI). Vaccine, 2004, 22, 547-550.	1.7	38

#	Article	IF	CITATIONS
19	Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine, 2015, 33, 6441-6452.	1.7	37
20	Vasculitic peripheral neuropathy: Case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1567-1578.	1.7	37
21	Evaluation of a multinational, multilingual vaccine debate on Twitter. Vaccine, 2016, 34, 6166-6171.	1.7	33
22	A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine, 2015, 33, 6453-6465.	1.7	32
23	Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine, 2009, 27, 2289-2297.	1.7	31
24	Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project. PLoS ONE, 2015, 10, e0130399.	1.1	29
25	Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 563-568.	1.7	28
26	Adverse events following immunization: perception and evidence. Current Opinion in Infectious Diseases, 2007, 20, 237-246.	1.3	27
27	Kawasaki disease and immunisation: A systematic review. Vaccine, 2017, 35, 1770-1779.	1.7	27
28	The Brighton Collaboration—enhancing vaccine safety. Vaccine, 2004, 22, 2046.	1.7	26
29	Safety assessment of immunization in pregnancy. Vaccine, 2017, 35, 6469-6471.	1.7	25
30	Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine, 2011, 29, 7559-7571.	1.7	22
31	Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. Vaccine, 2016, 34, 6007-6014.	1.7	22
32	Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581.	1.7	22
33	Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 586-591.	1.7	19
34	Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals, 2012, 40, 393-397.	0.5	19
35	Pediatric Drug Safety Signal Detection: A New Drug–Event Reference Set for Performance Testing of Data-Mining Methods and Systems. Drug Safety, 2015, 38, 207-217.	1.4	19
36	Evaluation of the Brighton Collaboration case definition of acute intussusception during active surveillance. Vaccine, 2006, 24, 1483-1487.	1.7	18

#	Article	IF	Citations
37	Template protocol for clinical trials investigating vaccines—Focus on safety elements. Vaccine, 2013, 31, 5602-5620.	1.7	17
38	Pandemic influenza vaccine & mp; narcolepsy: simulations on the potential impact of bias. Expert Review of Vaccines, 2016, 15, 573-584.	2.0	13
39	Procalcitonin for Diagnostics and Treatment Decisions in Pediatric Lower Respiratory Tract Infections. Frontiers in Pediatrics, 2017, 5, 183.	0.9	13
40	Safety of Co-Administration Versus Separate Administration of the Same Vaccines in Children: A Systematic Literature Review. Vaccines, 2020, 8, 12.	2.1	13
41	Drivers of antibiotic prescribing in children and adolescents with febrile lower respiratory tract infections. PLoS ONE, 2017, 12, e0185197.	1.1	13
42	Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis. Vaccine, 2016, 34, 6582-6596.	1.7	12
43	lgA vasculitis (Henoch–Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1559-1566.	1.7	9
44	Intussusception in children aged under two years in India: Retrospective surveillance at nineteen tertiary care hospitals. Vaccine, 2020, 38, 6849-6857.	1.7	9
45	Arthritis and arthralgia as an adverse event following immunization: A systematic literature review. Vaccine, 2019, 37, 372-383.	1.7	8
46	Interstrain Antigenic Variability of Mumps Viruses. Clinical Infectious Diseases, 2008, 46, 150-151.	2.9	7
47	Global Vaccine Safety Assessment. Pediatric Infectious Disease Journal, 2016, 35, 446-448.	1.1	7
48	Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. Vaccine, 2015, 33, 5333-5341.	1.7	6
49	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. Journal of Clinical Pharmacology, 2018, 58, S123-S139.	1.0	6
50	Intussusception in Young Children: Protocol for Multisite Hospital Sentinel Surveillance in India. Methods and Protocols, 2018, 1, 11.	0.9	6
51	Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6572-6581.	1.7	4
52	Reference set for performance testing of pediatric vaccine safety signal detection methods and systems. Vaccine, 2016, 34, 6626-6633.	1.7	4
53	Acute aseptic arthritis: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2019, 37, 384-391.	1.7	3
54	Adherence to the paediatric immunisation schedule in England. Vaccine: X, 2021, 9, 100125.	0.9	3

#	Article	IF	Citations
55	Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2019, 37, 392-399.	1.7	2
56	Co-administration of routine paediatric vaccines in England often deviates from the immunisation schedule. Vaccine: X, 2021, 9, 100115.	0.9	2
57	The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections. PLoS ONE, 2022, 17, e0264305.	1.1	2
58	Update on new vaccines and immunisation strategies. Current Paediatrics, 2006, 16, 1-7.	0.2	0